Three Vanderbilt technologies received US patent protection in the month of November. One invention includes a compound that targets positive allosteric modulation of the mGlu5 receptor for the treatment of neurological and psychiatric disorders. It was developed at Vanderbilt Center for Neuroscience Drug Discovery which is led by Vanderbilt neuroscientist P. Jeffrey Conn.
Also earning patent protection was a optical sensor that can detect chemical, biological, and explosive compounds. It was developed by Vanderbilt researchers Richard Haglund, David Cliffel, and David Wright, in collaboration with outside parties.
The final technology earning patent protection were a set of isolated nucleic acids that can be used to generate a mouse model of male infertility, for drug discovery screens, and for therapeutic treatment of fertility-related conditions. It was developed by Marie-Claire Orgebin-Crist and Robert Matusic of Vanderbilt, as well as an external researcher.